There is little information on the clinical course of transplantation from HCV-positive donors. However, it seems that there is no increased risk of acute liver failure after the procedure and that the presence of HCV-RNA in serum is necessary for transmission to take place. We report a case of allogeneic CD34-selected peripheral stem cell transplantation from an HCV-infected donor with viremia with a special clinical and virological course. After the selection procedure and cell washing we could not detect HCV-RNA by PCR in the wash buffer, but HCV-RNA was positive by PCR in the selected cells. Once the patient received the transfusion of the selected product HCV was detected in the PBMCs and at very low concentration in serum. HCV was also demonstrated in the hepatocytes with the in situ hybridization technique. In conclusion, we have shown that CD34 + cell selection from an HCV-positive allogeneic donor does not prevent HCV infection in the recipient. Our results also suggest that HCV replicates in PBMCs in vivo and that these cells release viral particles that can infect the liver. Keywords: hepatitis C virus; infected donor; stem cell transplantation; CD34 selection There is little information about the clinical and virological course of HCV infection in patients that receive a hematopoietic stem cell transplant (HSC) from an HCV infected donor. [1] [2] [3] [4] [5] In the present report we describe a case of HCV transmission from an HCV infected donor in a recipient who received an allogeneic transplantation from CD34-selected peripheral blood stem cells.
with hydroxyurea and HLA-typing revealed that he had an HLA-identical multiparous sister. His donor suffered from a histologically proven chronic active hepatitis C and presented abnormal ALT levels and thrombocytopenia (50 × 10 9 /l). Two years before she had been treated with interferon for 6 months without response. Our current treatment protocol for CML recommends performing the allogeneic BMT during the first year in those patients younger than 50 years and who have a sibling donor. However in this case, based on the HCV infection of the donor, we decided to start treatment with interferon and to perform a formal unrelated donor search. After 1 year with no cytogenetic response (100% Ph positive cells) and no A,B, DRB1 matched unrelated donor having been found, we decided to perform a CD34 selected allogeneic peripheral blood HSC from his HCV+ sister. This decision was based on the increased risk of conventional marrow harvest in a patient with chronic hepatitis and thrombocytopenia, and to avoid or at least decrease the amount of HCV transmitted from a conventional marrow or PBSC harvest. Both the patient and his donor gave written informed consent.
Hematopoietic progenitor mobilization and PBSC collection
Granulocyte colony-stimulating factor (G-CSF, Filgrastim; Amgen, Thousand Oaks, CA, USA) alone was administered at a dose of 10 g/kg once daily by subcutaneous injection for 5 days. Cells were collected by leukapheresis on the fifth and sixth day after starting G-CSF using a COBE Spectra continuous-flow blood-cell separator (COBE, Lakewood, CO, USA) and following standard procedures.
Positive selection of CD34
+ cells
Two consecutive harvests were used for immunoselection. The first of the two harvests was stored at 4°C and pooled the day after with the second leukapheresis product. CD34-positive selection was performed on day 0 after conditioning in order to infuse the final product into the recipient on the same day, thus avoiding cryopreservation. Immunoselection of CD34-positive cells was carried out using a system adapted to clinical use based on immunomagnetic beads following the manufacturer's guidelines. Separation was performed using commercial immunomagnetic separation columns on IsolexTM 300 (Baxter Healthcare, Munchen, Germany). Aliquots from the CD34-negative and CD34-positive fractions were taken from the sample installed on the column. They were used for cell counts, virological analysis, flow cytometric analysis and progenitor cell clonogenic assays.
Flow cytometry analysis

CD34
+ cells were evaluated by direct immunofluorescence on the pooled leukapheresis products and immunoselection fraction after incubation with CD34-PE conjugated MoAb (8G12; HPCA-2; Becton Dickinson, San José, CA, USA) using a FacSort cytometer (Becton Dickinson).
Results of selection of CD34
+ cells 
Transplantation procedure and clinical outcome
Busulfan and cyclophosphamide were employed for the conditioning regimen and the combination of cyclosporine A and prednisone for GVHD prophylaxis was used as previously described. 6 On day 0, the peripheral blood selected product was infused. A neutrophil and platelet engraftment was reached on day +18 and +17, respectively. No signs of acute or chronic GVHD appeared. On day +67 a bone marrow aspirate revealed complete hematopoietic engraftment and karyotypic analysis revealed 46XX in all the metaphases. Cyclosporine was tapered down from day +100 and stopped on day +216. On day +248 the patient relapsed into a lymphoid blast crisis of CML. The evolution was fatal with persistent leukemia in spite of two courses of chemotherapy and death occurred on day +346 after transplantation. The complications developed by the patient after CT included bilateral pneumonia and liver dysfunction with a maximum bilirubin level of 22 mg/dl and cholestatic features (increased GGT and AP with minimal changes in ALT levels). The biopsy results were compatible with chemotherapy-induced liver toxicity.
HCV-RNA detection in sera, blood cells and in liver biopsy
Peripheral blood mononuclear cells (10 7 cells) from both the donor and the recipient were isolated from fresh heparinized blood by centrifugation in a Ficoll-Hypaque gradient (Flow Laboratories, Irvine, UK). For the detection of HCV-RNA, total RNA from sera, from peripheral blood mononuclear cells (PBMCs) (from the donor and the recipient) and from CD34 + selected cells (from the donor) were isolated using the Trizol reagent (GIBCO BRL, Grand Island, NY, USA) following the instructions supplied by the manufacturers. CD34
+ selected cells and PBMCs were washed three times with ice-cold PBS buffer before RNA extraction. The last cell wash was conserved to be used as negative control in the detection of HCV-RNA. Presence of HCV-RNA was also tested in the eluate of the selection column, as well as in the PBS wash performed on the selected cells prior to the BMT.
HCV-RNA was tested by reverse transcription and nested polymerase chain reaction (RT-PCR) as previously described 7 using primers from the 5′ non-coding region of the HCV genome. To avoid false positive results, the contamination prevention measures described by Kwok and Higuchi were followed. 8 Positive (a serum sample from a chronic HCV carrier with abnormal ALT levels) and appropriate negative controls were tested in each PCR run.
To increase sensitivity, PCR negative serum samples from the recipient were clarified by centrifugation at 12 000 g for 10 min. The supernatant (1 ml) was layered on to a sucrose cushion consisting of 1 g/ml sucrose in TEN buffer (50 mm Tris-HCl pH 8.0, 1 mm EDTA and 150 mm NaCl) and centrifuged at 250 000 g for 24 h at 10°C in a Beckman SW60 Ti rotor (Beckman, Palo Alto, CA, USA). The pellet was resuspended in 250 l of sterile distilled water and, after the isolation of total RNA, RT-PCR was performed as described above.
HCV-RNA genotyping in the donor and the recipient was performed as described previously. 9 Two liver biopsies from the recipient were performed on days +310 and +346 post-transplantation. To assess whether HCV was present in the liver of the recipient, paraffin embedded liver sections were in situ hybridized using a 340 bp cDNA corresponding to the 5′ non-coding region of the HCV genome as a probe.
In situ hybridization technique as well as the specific controls employed were performed as described by Gosál-vez et al. 10 In the in situ hybridization experiments, slides from two patients with chronic hepatitis B and from two other patients with alcoholic hepatitis, all of them without HCV markers, were employed as negative controls.
HCV-RNA detection in the donor
HCV-RNA was positive in two serum samples taken from the donor on days −10 and −5 prior to BMT. Furthermore, HCV-RNA was positive in total PBMCs samples obtained on the same days as the serum samples ( Table 1 ). The last PBS wash of the cells performed before the RNA extraction was HCV-RNA negative.
On the other hand, HCV-RNA was positive in the CD34 + selected cells (Table 1) , while no viral RNA could be detected either in the eluate of the selection column or in the PBS wash performed on the selected cells prior to BMT. We did not study the presence of HCV-RNA in the cells that were not selected by the column. The genotype of the HCV-RNA isolated from serum PBMCs and CD34 + selected cells was 1b.
HCV-RNA detection in the recipient
HCV-RNA was negative by the conventional nested PCR in all the serum samples taken from the recipient prior to and after BMT. However after centrifugation of the serum samples, HCV-RNA was positive in the samples taken on days +150, +319 and +346 (Table 1) . On the contrary, HCV-RNA was positive in all PBMC samples available from the recipient ( Table 1) . As found in the donor, the HCV genotype in all positive samples was 1b.
Finally, viral RNA was found by in situ hybridization in the hepatocytes of the two liver biopsies obtained from the patient. Hybridization signals were mainly found in the cytoplasm and the percentage of positive hepatocytes was lower than 4% in both biopsies. Specificity of the HCV-RNA detection was demonstrated by the lack of signals in the negative control biopsies (Figure 1 ).
Discussion
The use of HCV-infected donors for SCT is a complex and difficult question since conflicting interests concerning medical and legal aspects can influence the decision. 2, 3 However when the benefit of the allogeneic SCT using an HCV positive donor is clearly superior to other therapeutic approaches and to the adverse complications associated with HCV infection, this option must be considered and it is important to try to avoid HCV transmission. There is little information on the potential infectivity of HCV-positive donors. In a prospective study, Shuhart et al 1 identified 12 marrow transplant recipients whose related donors tested positive for antibodies to HCV. After transplantation only those seven recipients from viremic donors (HCV-RNA in serum) acquired the infection without acute liver complications. On the contrary, results obtained in a prospective study performed by the European Group for Blood and Marrow Transplantation showed that not all patients who received a HSC from an infected donor with viremia became infected.
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In any case, as HCV viremia in the donor seems to be associated with the transmission of HCV infection to the recipient, strategies to decrease serum HCV-RNA concentration in the donor by interferon treatment or by selecting the cells to be transplanted should be considered. Regarding the interferon treatment, Vance et al 4 were able to avoid HCV transmission by treating an HCV-positive donor with alpha-interferon. However, only 25% of chronic HCV carriers will respond to interferon therapy. In the case of the selection of cells to be transplanted, it has been reported that only CD19 + B lymphocytes are infected by HCV. 5 Thus, selection of CD34 + cells could be a good approach to avoid HCV transmission.
In the present study we have found that HCV can be transmitted from infected peripheral blood mononuclear cells selected by a CD34 immunomagnetic column. Although after the selection procedure and cell washing we could not detect HCV-RNA by PCR in the wash buffer, HCV-RNA was positive by PCR in the selected cells. As mentioned above, it has been suggested that HCV selectively infects CD19
+ cells. 5 Since we did not perform an additional step to separate CD34
+ cells from B and T cells contained in the selected product, we cannot conclude which cell population was infected.
On the other hand, several authors have questioned the infection and replication of HCV in PBMCs suggesting that the detection of the negative strand of the HCV-RNA (the viral replicative intermediate) is a laboratory artefact. 12, 13 On the contrary, HCV has also been reported to be able to replicate in hematopoietic cells in vitro.
14 Our results strongly suggest that HCV also replicates in haematopoietic cells in vivo. As the eluate of the selection column and the PBS wash performed to the selected cells prior to the BMT were HCV-RNA negative, the only possible source of HCV infection in the recipient was the selected cells.
Our patient developed a very particular pattern of infection that could be influenced by the nature of transmission and by his immune status. For 1 year after transplantation the patient did not develop any antibodies against HCV as tested by the conventional ELISA test. This could be explained by the fact that the patient was under immunosuppressive therapy with cyclosporine for 6 months. In this sense, Locasciulli et al 15 have recently demonstrated that nearly 41% (20/48) of children cured of leukemia after a follow-up of 10 years did not develop anti-HCV although they were HCV-RNA positive in serum. On the other hand the first evidence of HCV infection in the recipient was the detection of HCV-RNA in a PBMC sample taken on day +72. While HCV-RNA was always positive in all PBMC samples tested thereafter during the follow-up, HCV-RNA in serum was only detectable at days +150, +319 and +346 after ultracentrifugation of the samples. This fact suggests that this patient had a very low viremia level. It can be argued that this viral RNA came from the lysis of circulating PBMCs, so that the patient was not truly infected by HCV. However, with in situ hybridization, we have demonstrated the presence of HCV-RNA in the hepatocytes of the two liver biopsies of this patient.
In conclusion, we have shown that CD34 + cell selection from an HCV-positive allogeneic donor does not prevent HCV infection in the recipient. Our results also suggest that HCV replicates in PBMCs in vivo and that these cells release viral particles that can infect the liver.
